Rahman, R.
The Christie NHS Foundation Trust
2 papers on CoChatORCID 0000-0003-0213-5999
Most cited papers
- Verified
725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M., Rahman, R., Little, M., Tunariu, N., Curcean, A., Badham, H., et al. (2021) · Annals of Oncology
Ovarian cancer diagnosis and treatmentOvarian function and disorders
Cited by 17
- Verified
Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research
Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free